Evaluation of the effect of 2 weeks treatment with CHF 4226 [carmoterol] pMDI [pressurised metered dose inhaler] 2microg and 4microg, given once daily in the morning, on 24-Hour FEV1 [forced expiratory volume in one second] in patients with COPD [chronic obstructive pulmonary disease].

Trial Profile

Evaluation of the effect of 2 weeks treatment with CHF 4226 [carmoterol] pMDI [pressurised metered dose inhaler] 2microg and 4microg, given once daily in the morning, on 24-Hour FEV1 [forced expiratory volume in one second] in patients with COPD [chronic obstructive pulmonary disease].

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Carmoterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2009 Primary endpoint 'Forced expiratory volume in 1 second' has been met.
    • 15 Sep 2009 Results were presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009).
    • 07 Jan 2009 Planned number of patients changed from 60 to 57 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top